



Financial Tear Sheet

Corporate Profile

Codexis, Inc. (Nasdaq: CDXS), is a leading developer of biocatalysts for the pharmaceutical and fine chemical industries. Codexis utilizes its proprietary CodeEvolver® directed evolution technology platform and CodeXporter® enzyme production platform, for the discovery, identification, optimization, and efficient production of enzymes for its customers. Customers include global leaders such as Merck, Pfizer and Teva. For more information, see www.codexis.com

Stock Performance

CDXS (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	\$7.30
Change (%)	▲ 0.03 (0.27%)
Volume	122,658
52 Week Low	\$3.60
Market Cap	\$352,768,171
Rolling EPS	-0.40
PE Ratio	N/A
Shares Outstanding	48,324,407

Data as of 10/20/17 4:00 p.m. ET



Recent News Releases

October 12, 2017

[Codexis and Nestlé Health Science Enter Into Healthcare-Focused Protein Engineering Platform Partnership](#)

Upcoming Events

There are currently no events scheduled.

SEC Filings

	Filing Date	Form
August 31, 2017 Codexis to Present at Four Investment Conferences in September	10/12/17	8-K
August 09, 2017 Codexis Reports Financial Results for the Second Quarter of 2017	09/25/17	SC 13G/A
	09/18/17	4
	09/08/17	8-K

Powered By **EDGAR**Online

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Minimum 20 minutes delayed